Today's Trend
Oscar Health, Inc. (NYSE: OSCR) reported a strong second-quarter 2026, initially supporting a higher stock price. However, investor concern about member churn and the durability of growth later overshadowed the earnings beat, causing the shares to weaken from their post-results advance.
- Substantial earnings and revenue beat: Oscar reported quarterly EPS of $1.10, versus the $0.40–$0.43 analyst consensus, compared with a $0.89 loss in the year-ago quarter. Revenue rose 70.4% to $4.88 billion, exceeding estimates of approximately $4.73 billion. Oscar Health Inc. Q2 Earnings Beat Estimates
- Profitability improved sharply: The insurer generated approximately $361 million of second-quarter profit and more than $1 billion in net income during the first half, helped by membership growth and easing medical costs. Oscar Health Reports Another Big Profit
- Full-year outlook was raised: Oscar increased its 2026 revenue forecast to $18.7 billion–$19.0 billion, above the roughly $18.6 billion consensus estimate, and indicated $500 million–$700 million in earnings from operations with an 81.5%–82.5% medical-loss-ratio target. Oscar Health Signals 2026 Earnings Outlook
- The results reinforce Oscar’s improving profit-turnaround story, with technology and operational execution remaining important to managing a changing customer base. Oscar Health 2026 Profit Turnaround
- Churn outlook pressured the shares: Management’s forecast for elevated member churn raised concerns about retention, future enrollment growth and whether the unusually strong earnings can be sustained. That concern reportedly outweighed the quarterly beat and guidance increase. Oscar Health Falls as Churn Forecast Overshadows Q2 Beat